|Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.|
|PMID: 23154554 Owner: NLM Status: MEDLINE|
|INTRODUCTION: Denosumab, a fully human anti-RANKL monoclonal antibody, reduces the incidence of skeletal-related events in patients with bone metastases from solid tumors. We present survival data for the subset of patients with lung cancer, participating in the phase 3 trial of denosumab versus zoledronic acid (ZA) in the treatment of bone metastases from solid tumors (except breast or prostate) or multiple myeloma.
METHODS: Patients were randomized 1:1 to receive monthly subcutaneous denosumab 120 mg or intravenous ZA 4 mg. An exploratory analysis, using Kaplan-Meier estimates and proportional hazards models, was performed for overall survival among patients with non-small-cell lung cancer (NSCLC) and SCLC.
RESULTS: Denosumab was associated with improved median overall survival versus ZA in 811 patients with any lung cancer (8.9 versus 7.7 months; hazard ratio [HR] 0.80) and in 702 patients with NSCLC (9.5 versus 8.0 months; HR 0.78) (p = 0.01, each comparison). Further analysis of NSCLC by histological type showed a median survival of 8.6 months for denosumab versus 6.4 months for ZA in patients with squamous cell carcinoma (HR 0.68; p = 0.035). Incidence of overall adverse events was balanced between treatment groups; serious adverse events occurred in 66.0% of denosumab-treated patients and 72.9% of ZA-treated patients. Cumulative incidence of osteonecrosis of the jaw was similar between groups (0.7% denosumab versus 0.8% ZA). Hypocalcemia rates were 8.6% with denosumab and 3.8% with ZA.
CONCLUSION: In this exploratory analysis, denosumab was associated with improved overall survival compared with ZA, in patients with metastatic lung cancer.
|Giorgio Vittorio Scagliotti; Vera Hirsh; Salvatore Siena; David H Henry; Penella J Woll; Christian Manegold; Philippe Solal-Celigny; Gladys Rodriguez; Maciej Krzakowski; Nilesh D Mehta; Lara Lipton; José Angel García-Sáenz; José Rodrigues Pereira; Kumar Prabhash; Tudor-Eliade Ciuleanu; Vladimir Kanarev; Huei Wang; Arun Balakumaran; Ira Jacobs|
Related Documents :
|23998404 - Preoperative concurrent chemoradiotherapy of s-1/cisplatin for stage iii non-small cell...
1951884 - Comparison of surgery and radiotherapy in t1 and t2 glottic carcinomas.
23617484 - Microsimulation model predicts survival benefit of radiofrequency ablation and stereota...
24977454 - A new perspective in the treatment of non-small-cell lung cancer (nsclc). role of afati...
3829014 - Cell kinetics as a prognostic marker in locally advanced breast cancer.
6305524 - High-dose cyclophosphamide with autologous marrow transplantation for small cell carcin...
|Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't|
|Title: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Volume: 7 ISSN: 1556-1380 ISO Abbreviation: J Thorac Oncol Publication Date: 2012 Dec|
|Created Date: 2012-11-16 Completed Date: 2013-05-07 Revised Date: 2013-09-09|
Medline Journal Info:
|Nlm Unique ID: 101274235 Medline TA: J Thorac Oncol Country: United States|
|Languages: eng Pagination: 1823-9 Citation Subset: IM|
|Department of Clinical and Biological Sciences, University of Turino, Orbassano, Italy. firstname.lastname@example.org|
|APA/MLA Format Download EndNote Download BibTex|
Antibodies, Monoclonal, Humanized / therapeutic use*
Bone Density Conservation Agents / therapeutic use*
Bone Neoplasms / drug therapy, mortality*, secondary
Carcinoma, Non-Small-Cell Lung / drug therapy, mortality*, pathology
Carcinoma, Squamous Cell / drug therapy, mortality, pathology
Diphosphonates / therapeutic use*
Imidazoles / therapeutic use*
Lung Neoplasms / drug therapy, mortality*, pathology
RANK Ligand / antagonists & inhibitors
Small Cell Lung Carcinoma / drug therapy, mortality, pathology
|0/Antibodies, Monoclonal, Humanized; 0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Imidazoles; 0/RANK Ligand; 118072-93-8/zoledronic acid; 4EQZ6YO2HI/denosumab|
|J Thorac Oncol. 2013 Aug;8(8):e79
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical s...
Next Document: Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by secon...